MGMT and glioblastoma: Patients with GBM exhibiting a methylated MGMT promoter tend to have better treatment outcomes, as they are less able to proficiently repair the damage caused by alkylating agents, compared with those possessing unmethylated promoters who often show poor responses [16, 55, 56].